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http://dx.doi.org/10.1016/j.asjsur.20Summary Objective: To compare the safety and efficacy of transurethral plasmakinetic
resection of the prostate (PKRP) versus transvesical prostatectomy (TVP) in the treatment of
large-volume benign prostatic hyperplasia (LV-BPH) (100e149 mL).
Methods: Ninety-nine BPH patients who had a prostate volume of 100e149 mL were divided
into two groups to undergo PKRP or TVP. Preoperative clinical data were analyzed. Patients
had follow-up appointments at 1 month, 3 months, 6 months, and 12 months postoperatively.
Outcome measures included the International Prostate Symptom Score, quality of life score,
maximum urinary flow rate, and postvoid residual urine volume. Adverse effects were also re-
corded.
Results: A total of 96 patients completed the 12-month follow-up. The operative time was
longer, but intraoperative blood loss was lower in the PKRP group. Despite a higher percentage
of patients requiring a blood transfusion, there was an obvious advantage in gland removal rate
in the TVP group. The duration of postoperative catheterization, bladder irrigation, and hos-
pital stay was significantly shorter in the PKRP group. Outcome measures were significantly
improved in both groups 1 month postoperatively. The improvement in lower urinary tract
symptoms was maintained throughout the 12 months after surgery. There were no significant
differences in International Prostate Symptom Score, quality of life, maximum urinary flow
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Prostatectomy for benign prostatic hypertrophy 59Conclusion: PKRP has the advantage over TVP of being minimally invasive in the treatment of
LV-BPH while achieving the same postoperative outcomes.
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reserved.1. Introduction
Prostate volume is an important factor that affects the
treatment of benign prostatic hyperplasia (BPH).1 Surgical
treatment of large-volume BPH (LV-BPH) poses a challenge
to urologists. Although transurethral resection of the
prostate (TURP) is considered the “gold standard” for sur-
gical treatment of BPH,2 the relatively long operative time,
low efficiency of resection, and high incidence of post-
operative complications (e.g., intraoperative and post-
operative bleeding, postoperative hyponatremia, and
urethral stricture) have limited its application in the
treatment of LV-BPH.3 Open surgery is the main treatment
option for LV-BPH because of its shorter operative time,
complete gland removal, and significant postoperative
improvement in lower urinary tract symptoms.4e6 However,
given the advances in minimally invasive techniques, the
use of traumatic open surgery for the treatment of LV-BPH
is being increasingly disputed.7e9 Transurethral plasmaki-
netic resection of the prostate (PKRP) is a relatively new
minimally invasive procedure that has been used for the
treatment of LV-BPH.10 Having the advantages of accurate
incision, good hemostasis, and “capsule recognition”
function, PKRP can effectively prevent capsular perfora-
tion.11 Moreover, PKRP can avoid the occurrence of tran-
surethral resection syndrome (TURS) because normal saline
is used as the irrigation solution.12 Thus, PKRP is expected
to replace TURP as the new “gold standard” treatment for
BPH. However, there have been no previous studies evalu-
ating the safety and efficacy of PKRP in the treatment of LV-
BPH.
In the present study, we conducted a prospective ran-
domized clinical trial to compare the safety and efficacy of
PKRP versus transvesical prostatectomy (TVP) in the
treatment of LV-BPH. Although many consider a large
prostate volume as >80 mL or >100 mL, there remains a
great deal of controversy about the definition of LV-BPH.
The prostate volume in some BPH patients can be
>500 mL.13e17 In this study, we attempted to define large
and huge prostate volumes as 100e149 mL and >150 mL,
respectively. For the purpose of this study, all BPH patients
with prostate volume ranging from 100 mL to 149 mL were
considered to have LV-BPH.
2. Patients and methods
2.1. Patients
A total of 99 patients with LV-BPH (100e149 mL), who were
treated from January 2005 to October 2010 at the Third
Xiangya Hospital of Central South University, were included
in this prospective trial. Preoperative clinical data for allthe patients were analyzed, including age, medical history,
International Prostate Symptom Score (IPSS), quality of life
(QoL), digital rectal examination (DRE), prostate-specific
antigen (PSA), maximum urinary flow rate (Qmax), prostate
volume, postvoid residual urine volume (PVR), hemoglobin
(Hb) concentration, and serum sodium (Naþ) concentration.
Transrectal ultrasound (TRUS) was used to measure the
maximum length (L), width (W), and anteroposterior height
(H) of the prostate to calculate the prostate volume using
the prostate ellipse formula: prostate volume
(mL) Z 0.52  L  W  H.18 Patients underwent an
ultrasound-guided transrectal prostate biopsy if the PSA
level was >4 ng/mL, the DRE was abnormal, or suspicious
lesions were suggested by TRUS. Patients were given a
thorough explanation about the advantages and possible
risks of both modes of treatment. Written informed consent
was obtained preoperatively from each patient. The
included patients were divided into two groups by a urol-
ogist who was not involved in the surgery to undergo PKRP
(n Z 50) or TVP (n Z 49). The study was approved by the
local ethics committee.
The inclusion criteria were as follows: patients >60
years of age; able to tolerate surgery and anesthesia; not
taking anticoagulant drugs or discontinuing anticoagulant
drugs for 2 weeks; refusing to receive medical treatment
or having failed in conservative medical treatment; QoL
severely affected by lower urinary tract symptoms; one or
more complications, such as recurrent urinary retention,
gross hematuria, recurrent urinary tract infections, bladder
stones, and secondary liquid accumulation in the upper
urinary tract as a result of BPH; able to understand and sign
informed consent; and able to complete follow-up as
required. Exclusion criteria were neurogenic bladder; pre-
vious bladder, prostate or urinary tract surgery; urethral
stricture; and known bladder or prostate cancer.
2.2. Surgical procedures
An experienced surgeon performed all surgeries. PKRP was
performed using a bipolar plasmakinetic cutting wire loop
(Gyrus Medical, Cardiff, UK) at a power setting of 160 W for
cutting and 80 W for coagulation. A 0.9% sodium chloride
solution was used to irrigate the area continuously. The 27F
sheath was inserted to observe the changes in the urethral
and bladder mucosa. According to the modified Nesbit
procedure, an incision was made at the 6 o’clock position of
the bladder neck to the proximal verumontanum to create
a longitudinal marking groove that was extended to the
verumontanum and carried down to the surgical capsule,
with complete removal of the prostatic stroma. Then,
another marking groove was made via an incision from the
11 o’clock to 1 o’clock position using the same method.
Finally, the left and right lateral lobes of the prostate were
Table 1 Preoperative clinical data between the PKRP and
TVP groups.
PKRP (n Z 50) TVP (n Z 49) p
Age (y) 70.4  6.4 71.3  5.9 0.475
Medical history (mo) 69.8  56.5 83.7  48.6 0.195
Prostate volume (mL) 116.6  12.6 118.2  13.3 0.529
Qmax (mL/s) 4.9  3.2 6.0  3.1 0.087
IPSS 25.7  7.9 26.6  6.9 0.562
QoL score 4.9  0.8 5.2  0.9 0.115
PVR (mL) 70.3  22.2 64.2  18.9 0.150
Naþ (mmol/L) 139.8  2.4 139.6  2.8 0.608
PSA (ng/mL) 10.4  9.8 12.1  14.1 0.486
Hemoglobin (g/dL) 11.5  1.3 11.2  1.7 0.341
IPSS Z International Prostate Symptom Score;
PKRP Z plasmakinetic resection of the prostate;
PVRZ postvoid residual urine volume; PSAZ prostate-specific
antigen; QmaxZ maximum urinary flow rate; QoLZ quality of
life; TVP Z transvesical prostatectomy.
Table 2 Perioperative and postoperative parameters
between the PKRP and TVP groups.
PKRP (n Z 49) TVP (n Z 47) p
Operation time (min) 75.8  17.3 55.4  11.3 <0.05
Tissue retrieved (g) 76.0  12.6 98.7  14.9 <0.001
Gland removal rate (%) 65.0  6.9 83.2  3.9 <0.001
Hb loss (g/dL) 1.2  0.7 1.9  0.9 <0.001
Naþ loss (mmol/L) 0.4  0.5 0.3  0.5 0.159
Irrigation time (d) 1.4  0.6 2.4  0.8 <0.001
Catheter removal (d) 5.6  0.9 10.4  1.2 <0.001
Hospital stay (d) 6.5  0.8 11.5  1.2 <0.001
PKRP Z plasmakinetic resection of the prostate;
TVP Z transvesical prostatectomy.
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o’clock positions of the bladder neck. If the bladder neck
was relatively high or there was a significant annulus
around the bladder neck, part of the annulus was removed
before the end of the procedure to eliminate the “doorsill
phenomenon”. If bladder stones were present, transure-
thral cystoscopic holmium laser lithotripsy with a power of
80 W was performed before the PKRP procedure. A three-
way 20F Foley silicone catheter was introduced at the end
of the procedure. The TVP procedure was performed as
previously described.19 An 8-cm longitudinal incision was
made above the pubis to open the bladder. A circumfer-
ential incision was then made around the urethral orifice at
the bladder neck to incise the bladder mucosa over the
prostate and the prostate capsule. After blunt dissection of
the prostate, the bladder was closed with a running 2-
0 absorbable suture. A 28F mushroom-bladder catheter and
a two-way 20F Foley silicone catheter were inserted after
the procedure. The catheter balloon was filled with 30 mL
water, and continuous traction of the bladder neck was
performed for 6e12 hours. Continuous bladder irrigation
was initiated in all patients until the irrigation solution
became clear. The bladder catheter was removed when the
color of the urine turned clear without continuous saline
irrigation, while the urethral catheter was removed 2 or 3
days after bladder catheter removal when the fistula
closed.
2.3. Postoperative outcome measures
Postoperative outcome measures included the operative
time of prostate resection (the operative time of holmium
laser lithotripsy was not included); loss of Hb [g/dL Hb
(preoperative) e g/dL Hb (at the end of the procedure)];
loss of Naþ [mmol/L Naþ(preoperative) e mmol/L Naþ (at
the end of the procedure)]; removed gland weight;
gland removal rate (% weight removed/preoperative
volume  100); and the duration of continuous post-
operative bladder irrigation, catheterization, and hospital
stay. Intraoperative and postoperative complications were
recorded, including blood transfusion, hemostasis, ure-
thral stricture, hyponatremia, incontinence, urinary tract
infections (colony count 105 colony-forming units/mL for
clean midstream urine samples), and recatheterization.
All patients were followed up at 1 month, 3 months, 6
months and 12 months postoperatively. Postoperative
follow-up outcome measures included IPSS, QoL, Qmax,
and PVR. During the follow-up period, one patient in the
PKRP group could not be contacted after discharge.
Two patients in the TVP group were lost to follow-up
due to the change of address at 3 months and 12 months
after surgery, respectively. Thus, a total of 96 patients
(PKRP, n Z 49; TVP, n Z 47) completed the 12-month
follow-up.
2.4. Statistical analysis
Statistical analysis was performed using SPSS 13.0 software
package (SPSS, Inc., Chicago, IL, USA). Preoperative, peri-
operative, and postoperative data were expressed as
mean  standard deviation and compared using theStudent’s t test. The incidence of postoperative complica-
tions was compared using the c2 test, and p values <0.05
were considered statistically significant.
3. Results
Ninety-nine patients with LV-BPH were initially enrolled in
the study. Table 1 shows the preoperative clinical data for
patients in the two groups, and there were no significant
differences.
The perioperative results (Table 2) suggested that,
although the operative time was 20.4 min longer for the
PKRP group than the TVP group, the duration of bladder
irrigation, catheterization and hospital stay was shorter in
the PKRP group. There was more Hb loss in the TVP group,
but the gland removal rate was 18.2% higher for the TVP
group than the PKRP group. There was no difference in
postoperative serum Naþ loss between the two groups.
During the follow-up period, results showed that in both
groups, the IPSS, QoL, Qmax, and PVR were all improved
after surgery (Table 3). IPSS had a higher degree of
improvementat 1 month postoperatively in the PKRP group
than in the TVP group, but showed no significant
Table 3 Postoperative follow-up outcome measures in the PKRP (n Z 49) and TVP (n Z 47) groups.
Baseline 1 mo 3 mo 6 mo 12 mo
IPSS
PKRP 25.7  7.9 9.5  1.7 10.4  1.2 9.0  1.9 8.9  1.6
TVP 26.6  6.9 10.5  1.5 10.5  1.4 8.4  2.4 8.8  2.0
p 0.562 0.002 0.880 0.129 0.947
QoL
PKRP 4.9  0.8 2.3  0.5 2.1  0.6 1.9  0.5 2.0  0.5
TVP 5.2  0.9 2.5  0.5 2.2  0.6 2.1  0.6 2.2  0.6
p 0.115 0.196 0.480 0.294 0.269
Qmax (mL/s)
PKRP 4.9  3.2 14.7  3.4 15.9  3.9 16.5  3.4 16.3  3.2
TVP 6.0  3.1 15.4  4.1 16.7  4.0 17.3  3.8 17.4  3.0
p 0.087 0.396 0.336 0.302 0.098
PVR (mL)
PKRP 70.3  22.2 24.8  5.6 21.6  5.7 20.1  5.3 19.0  5.5
TVP 64.2  18.9 25.9  5.7 19.9  5.7 18.8  5.8 17.8  5.4
p 0.150 0.329 0.150 0.248 0.268
IPSSZ International Prostate Symptom Score; PKRPZ plasmakinetic resection of the prostate; PVRZ postvoid residual urine volume;
Qmax Z maximum urinary flow rate; QoL Z quality of life; TVP Z transvesical prostatectomy.
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operatively between the two groups. The QoL, Qmax and
PVR results showed no significant differences between the
PKRP and TVP groups (Table 3).
The incidences of postoperative complications of the
two groups are shown in Table 4. Intraoperative hypona-
tremia did not occur in either group. Postoperative urinary
tract infections occurred in both groups, with an incidence
of 4.1% in the PKRP group and 6.4% in the TVP group. No
patients in the PKRP group required a postoperative blood
transfusion, whereas three patients (all with Hb loss >5 g/
dL) in the TVP group were transfused with 1e3 units of
blood and underwent hemostasis treatment. Of the three
patients who underwent blood transfusion, two required
hemostasis via cystoscopic bladder blood clot removal
surgery under continuous epidural anesthesia. However,
there was no significant difference in the percentage of
patients requiring blood transfusion between the two
groups (p > 0.05). After catheter removal, three (6.1%)
patients in the PKRP group and two (4.3%) in the TVP group
could not urinate and required the catheter to beTable 4 Postoperative complications in the PKRP and TVP
groups.
PKRP (n Z 49) TVP (n Z 47) p
Blood transfusion 0 3 (6.4%) 0.072
Hemostasis 0 2 (4.3%) 0.144
Urethral stricture 3 (6.1%) 0 0.085
Hyponatremia 0 0 d
Temporary incontinence 3 (6.1%) 4 (8.5%) 0.653
Urinary tract infections 2 (4.1%) 3 (6.4%) 0.480
Recatheterization 3 (6.1%) 2 (4.3%) 0.520
PKRP Z plasmakinetic resection of the prostate;
TVP Z transvesical prostatectomy.reinserted (pZ 0.520). All of them could urinate 4e6 days
later. After catheter removal, three (6.1%) patients in the
PKRP group and four (8.5%) in the TVP group had mild uri-
nary incontinence (p Z 0.653). Through the utilization of
pelvic floor muscle training, the urinary incontinence
problem was resolved in all of them by 3 months
postoperatively.
The PKRP group had a higher incidence of urethral
stricture than the TVP group had (6.1% vs. 0, p Z 0.085).
Three patients in the PKRP group had a urethral stricture,
including one case of urethral external orifice stricture and
two cases of membranous urethral stricture. The patient
with a urethral external orifice stricture underwent ure-
thral dilatation. The patients with a membranous urethral
stricture were treated by transurethral holmium laser
incision with postoperative urethral dilatation on a regular
basis (for 4e6 weeks). The postoperative recovery of uri-
nation was satisfactory. Qmax was >15 mL/s in all patients.
In addition, no postoperative complications of other sys-
tems (i.e., pulmonary and cardiovascular systems)
occurred.
4. Discussion
TURP has comparable efficacy to open surgery in the
treatment of small- and medium-volume BPH, but is
associated with faster postoperative recovery and shorter
hospital stay, which makes TURP the primary choice for
surgical treatment of BPH. However, the application of
TURP to the treatment of LV-BPH is limited due to the
disadvantages mentioned in the Introduction section.
Although open prostatectomy is considered to be the ideal
treatment for LV-BPH,4,7e9,20 many BPH patients are
reluctant to undergo open surgery due to trauma,
bleeding, and the prospect of a long hospital stay. Gratzke
et al9 performed open surgery on 902 BPH patients with an
average prostate volume of 96.3  37.4 mL and found that
62 Z. Long et al.the total incidence of postoperative complications
reached 17.3%. Of all patients tested, two (0.2%) died, 68
(7.5%) received a blood transfusion, 46 (5.1%) contracted
a urinary tract infection, and 33 (3.7%) had severe
bleeding.
PKRP is a new form of TURP that is applicable in the
majority of BPH patients with bladder outflow
obstruction.21e24 The formation of a highly focused ionized
plasma area around the electrodes leads to quick cutting
action and the formation of a uniform solidified layer,
3e5 mm in depth, that functions in hemostasis.25,26 There
is no need for the use of a negative plate during surgery,
and no current flows through the body. Therefore, PKRP is
particularly suitable for patients with a pacemaker. The
biggest advantage of PKRP is the use of 0.9% normal saline
as the irrigation medium, which has little effect on the
internal environment of the body.27 Therefore, PKRP can
effectively prevent the occurrence of TURS.28 Moreover,
the cutting action of PKRP is related to the resistance of
the tissue. As the resistances of hyperplastic gland and
capsule are somewhat different, the capsule is resected
with relatively low efficiency. Therefore, it is difficult to
cut through the capsule, which further reduces the risk of
developing TURS.12 In our clinical trial, although the
operative time of PKPR was longer than that of TVP
(75.8  17.3 minutes vs. 55.4  11.3 minutes, p < 0.05),
there was less intraoperative loss of Hb (1.2  0.7 g/dL vs.
1.5  0.9 g/dL, p < 0.05) in the PKPR group, and none of
the patients in the PKPR group required a blood trans-
fusion, suggesting that PKPR is a minimally invasive pro-
cedure compared to TVP.
The surface temperature of plasma is <70C when it
acts on prostate tissue. With this small thermal effect,
PKPR has the advantage of not easily damaging the ver-
umontanum and external sphincter (especially the erectile
nerves). Therefore, the incidence of postoperative bladder
irritation is decreased. Moreover, the incidence of sec-
ondary hemorrhage and urinary tract infections resulting
from tissue necrosis also decreases, which is conducive to
postoperative recovery. Consistent with these facts, our
results show that the duration of postoperative bladder
irrigation, catheterization, and hospital stay was signifi-
cantly shorter in the PKRP group than in the TVP group
(1.4  0.6 days vs. 2.4  0.8 days, 5.6  0.9 days vs.
10.4  1.2 days, 6.5  0.8 days vs. 11.5  1.2 days;
p < 0.001 for all). This observation is in agreement with the
result of a recently published study.29 Taken together,
these findings suggest that PKRP has an advantage over TVP
in terms of faster postoperative recovery in the manage-
ment of LV-BPH.
Although the removal efficiency of PKRP was lower than
that of TVP (65.0  6.9% vs. 83.2  3.9%, p < 0.001), there
was no difference in the improvement in urination between
the two groups. Patients in both groups had significant
improvement in urinary function scores, except for IPSS at 1
month follow-up (9.5  1.7 (PKRP) vs. 10.5  1.5 (TVP),
p Z 0.002). The improvement in lower urinary tract
symptoms in both groups was maintained during the post-
operative follow-up from 3 months to 12 months, showing
no significant difference between the two groups
(p > 0.05). One previous clinical trial comparing the tran-
surethral plasmakinetic enucleation of the prostate andPKRP showed that IPSS, QoL, Qmax, and PVR were all
significantly improved 3 months postoperatively and that
there were no differences between the two groups.30
Therefore, as long as the median and both lateral lobes
of the hyperplastic gland are effectively removed during
PKRP, which eliminates bladder outlet obstruction and
lower urinary tract symptoms, PKRP can achieve the same
efficacy as TVP, even if it does not reach the gland removal
rate of TVP.
Although PKRP has a significant advantage of being
minimally invasive compared to TVP, the incidence of ure-
thral stricture associated with the PKRP procedure could
not be neglected in our study (6.1% for the PKRP group).
The preoperative presence of urethritis, a relatively large
plasmakinetic resectoscope sheath (it may be a little too
large for Asians), the long duration of the irritation of the
mucous membrane of the urethra during surgery, and the
surgeon’s rough handling were all likely to be the reasons
for urethral injury. The main sites of injury were the ure-
thral external orifice and the membranous urethra. Both
the failure to complete timely repair of urethral injury and
irritation from complicated postoperative urethritis could
cause urethral stricture. Once the urethral stricture was
confirmed, remedies including the incision of the stricture
ring and regular urethral dilatation should be used. Effec-
tive measures to reduce the incidence of urethral stricture
include preoperative objective assessment of the patient’s
urethral condition by urinary tract imaging, the avoidance
of rough handling during surgery, shortening operative
time, and active postoperative antibiotic usage. Timely
urethral dilatation for patients that may have urethral
stricture could reduce the risk of having to undergo a sub-
sequent transurethral surgery.
The incidence of other adverse events, such as tempo-
rary urinary incontinence (6.1% for PKRP vs. 8.5% for TVP),
urinary tract infections (4.1% for PKRP vs. 6.4% for TVP),
and recatheterization (6.1% for PKRP vs.4.3% for TVP),
showed no significant differences between the PKRP and
TVP groups (p > 0.05 for all). The main reasons for tem-
porary urinary incontinence may be related to local in-
flammatory edema, a failure of the external sphincter
mechanism, bladder instability or a decrease in bladder
compliance, and excessive elongation of the external
sphincter due to long-term compression from the hyper-
plastic gland. In our study the urinary incontinence was not
caused by sphincter damage. Through a period of pelvic
floor muscle training, all of the patients were able to
recover on their own.
Besides PKRP, there are several other effective and
minimally invasive treatments currently available for
prostatectomy to minimize the chance of bleeding and TUR
syndrome, such as transurethral laser prostatectomy and
photoselective vaporization.31 Most of the lasers for pros-
tatectomy have lower bleeding and less water toxicity than
TURP has.31,32 In particular, laser enucleation of the pros-
tate is as effective as open prostatectomy in the manage-
ment of very large prostate glands.32 Compared with PKRP,
holmium laser enucleation of the prostate is associated
with less risk of hemorrhage, shorter bladder irrigation and
catheter times, and reduced hospital stay.33 Of note,
although traditional TURP using distilled water in managing
LV-BPH carries a higher risk of TURS due to prolonged
Prostatectomy for benign prostatic hypertrophy 63operation time, and PKRP can compensate for this weak
point, distilled water provides better vision than normal
saline and enables a quicker procedure that leads to less
bleeding and less water shifting into the body. With regard
to the fact that TURS does not have a high incidence and
can be treated with intraoperative diuretics, PKRP is not
inferior to TURS alone. However, combination of PKRP with
laser vaporization may combine the advantages of both
techniques and provide a safer and more effective method
for the treatment of LV-BPH.34
The current study was limited in that patients were not
randomly assigned, which may have led to imbalances in
risk factors between the two groups and biased estimates
of treatment effects. Another limitation of our study was
the relatively small sample size with limited statistical
power. Finally, the follow-up time was relatively short.
Future studies should be carefully designed to address
these issues.
In conclusion, our clinical trial shows that PKRP has
the advantage of being minimally invasive over TVP in the
treatment of LV-BPH (100e149 mL), while achieving the
same postoperative outcomes. Therefore, PKRP is a safe
and effective treatment method for LV-BPH. However,
future studies with more patients and a longer follow-up
time are needed to evaluate further the safety and efficacy
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